Welcome to Peptide Card of AntiTbPdb
This page displays user query in tabular form. |
KRWWKWIRW details |
Primary information | |
---|---|
ID | antitb_1219, |
Name | 23231581 |
N-Terminal modification | Cathelicidin HHC-10 |
C-Terminal Modification | KRWWKWIRW |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 9 |
Source | L |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium bovis |
In Vitro/ In vivo | Mycobacterium tuberculosis complex bacteria, Mycobacterium bovis bacille calmette guerin (BCG) (Mycobacterium bovis BCG Pasteur 1173P2) |
Cell Line | 69 % decrease in CFU at 50 μg/ ml |
Inhibition Concentration | Both |
Sequence | 2013 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | 8–9 weeks old C57BL/6 mice |
Mechanism of Action | CFUs in mouse lungs were reduced 77.8% at 1.25 mg |
Target | Significant reduction of IFN-γ transcription |
Combination Therapy | Cell envelope disruption |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and S. aureus etc |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1220, |
Name | 23231581 |
N-Terminal modification | Cathelicidin HHC-10 |
C-Terminal Modification | KRWWKWIRW |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 9 |
Source | L |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium bovis |
In Vitro/ In vivo | Mycobacterium tuberculosis complex bacteria, Mycobacterium bovis bacille calmette guerin (BCG) (Mycobacterium bovis BCG Pasteur 1173P2) |
Cell Line | 88 % decrease in CFU at 100 μg/ ml |
Inhibition Concentration | Both |
Sequence | 2013 |
Cytotoxicity | None |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | 8–9 weeks old C57BL/6 mice |
Mechanism of Action | CFUs in mouse lungs were reduced 95.8% at 2.5 mg k |
Target | Significant reduction of IFN-γ transcription |
Combination Therapy | Cell envelope disruption |
Other activities | Cell envelope |
PMID | None |
Year of Publication | Antibacterial (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and S. aureus etc |
Tertiary Structure (Technique) | Not Predicted), |